1.Progress in the relationship between heat shock protein 27 and ischemia-reperfusion injury
Sunyi YE ; Shusen ZHENG ; Jian WU
International Journal of Surgery 2010;37(5):322-326
Heat shock protein 27 is a small kind of protein which is produced under stress. HSP 27 is highly conservative, and plays an important role in ischemia-reperfusion injury. With the development of organ transplantation technique,the transplantation of heart,liver,kidney becomes more and more popular, the ischemia-reperfusion injury is a significant part of the management of these procedures. The endogenic research against the injury becomes more vital. This article is the first review of the relationship between heat shock protein 27 and ischemiareperfusion injury.
2.All-stage targeted therapy for the brain metastasis from triple-negative breast cancer.
Zimiao LUO ; Sunyi WU ; Jianfen ZHOU ; Weixia XU ; Qianzhu XU ; Linwei LU ; Cao XIE ; Yu LIU ; Weiyue LU
Acta Pharmaceutica Sinica B 2023;13(1):359-371
Brain metastasis is a common and serious complication of breast cancer, which is commonly associated with poor survival and prognosis. In particular, the treatment of brain metastasis from triple-negative breast cancer (BM-TNBC) has to face the distinct therapeutic challenges from tumor heterogeneity, circulating tumor cells (CTCs), blood-brain barrier (BBB) and blood-tumor barrier (BTB), which is in unmet clinical needs. Herein, combining with the advantages of synthetic and natural targeting moieties, we develop a "Y-shaped" peptide pVAP-decorated platelet-hybrid liposome drug delivery system to address the all-stage targeted drug delivery for the whole progression of BM-TNBC. Inherited from the activated platelet, the hybrid liposomes still retain the native affinity toward CTCs. Further, the peptide-mediated targeting to breast cancer cells and transport across BBB/BTB are demonstrated in vitro and in vivo. The resultant delivery platform significantly improves the drug accumulation both in orthotopic breast tumors and brain metastatic lesions, and eventually exhibits an outperformance in the inhibition of BM-TNBC compared with the free drug. Overall, this work provides a promising prospect for the comprehensive treatment of BM-TNBC, which could be generalized to other cell types or used in imaging platforms in the future.